Your patients with treatment-resistant hypertension may be at markedly increased risk for cardiovascular events. How will you manage them? Join us for lunch and a review of recent evidence on treatment-resistant hypertension—its impact and contribution to cardiovascular risk, as well as the efficacy of its conventional pharmacotherapeutic regimens and emerging therapies.

Activity Chair

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor, Tulane University School of Medicine
New Orleans, LA

Faculty

David A. Calhoun, MD
Professor of Medicine
Medical Director, Vascular Biology and Hypertension Program
The University of Alabama at Birmingham
Birmingham, AL

Carl (Chip) Lavie, Jr, MD, FACC, FACP, FCCP
Medical Director, Cardiac Rehabilitation and Preventive Cardiology
Director, Exercise Laboratories
John Ochsner Heart and Vascular Institute
Professor of Medicine
Ochsner Clinical School-the University of Queensland School of Medicine
New Orleans, LA